-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, L1ztsxSWIws61XDetnI6yQzx0nfUlc4rn7baNaCXBF09gGl0VQZIjPEo+FnkkbUv 9Huu4Isa5abLoQ0noyNYng== 0000914062-03-000281.txt : 20030403 0000914062-03-000281.hdr.sgml : 20030403 20030403162440 ACCESSION NUMBER: 0000914062-03-000281 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20030331 ITEM INFORMATION: Other events ITEM INFORMATION: Financial statements and exhibits FILED AS OF DATE: 20030403 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CRYOLIFE INC CENTRAL INDEX KEY: 0000784199 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090] IRS NUMBER: 592417093 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-13165 FILM NUMBER: 03638895 BUSINESS ADDRESS: STREET 1: 1655 ROBERTS BOULEVARD N W STREET 2: STE 142 CITY: KENNESAW STATE: GA ZIP: 30144 BUSINESS PHONE: 7704193355 MAIL ADDRESS: STREET 1: 1655 ROBERTS BOULEVARD N W STREET 2: STE 142 CITY: KENNESAW STATE: GA ZIP: 30144 8-K 1 cryolife8k403.txt FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2003 CRYOLIFE, INC. (Exact name of registrant as specified in its charter) Florida (State or other jurisdiction of incorporation) 1-13165 59-2417093 (Commission File Number) (IRS Employer Identification No.) 1655 Roberts Boulevard N.W., Kennesaw, Georgia 30144 ---------------------------------------------------- (Address of principal executive offices, including zip code) (770) 419-3355 (Registrant's telephone number, including area code) N/A (Former name or former address, if changed since last report) ITEM 5. OTHER EVENTS. On March 31, 2003, CryoLife, Inc. issued a press release disclosing that it had reached a settlement with the Estate of Brian Lykins. A copy of the press release is attached as Exhibit 99.1. ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS. (a) Financial Statements. Not applicable. (b) Pro Forma Financial Information. Not applicable. (c) Exhibits. Exhibit Number Description -------------- ----------- 99.1 March 31, 2003 Press Release regarding settlement of Lykins lawsuit 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, CryoLife has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CRYOLIFE, INC. Date: April 3, 2003 By: /s/ D.A. Lee ------------------------------------- Name: D. Ashley Lee Title: Vice President, Chief Financial Officer and Treasurer 3 EXHIBIT INDEX Exhibit Number Description - -------------- ----------- 99.1 March 31, 2003 Press Release regarding settlement of Lykins lawsuit 1604691v2 EX-99.1 3 cryolife8k403ex99.txt PRESS RELEASE EXHIBIT 99.1 FOR IMMEDIATE RELEASE CONTACTS: D. ASHLEY LEE VICE PRESIDENT, CHIEF FINANCIAL OFFICER (770) 419-3355 KATIE BRAZEL VICE PRESIDENT, FLEISHMAN HILLARD (404) 739-0111 CRYOLIFE SETTLES LAWSUIT ATLANTA, March 31, 2003 CryoLife Inc. (NYSE: CRY), a human tissue processing and medical device company, today announced that a settlement has been reached in the lawsuit brought against the Company by the estate of Brian Lykins. The lawsuit alleged the St. Cloud, Minnesota man received infected tissue during knee surgery. Terms of the settlement will not be disclosed. CryoLife believes that the Company has adequate insurance remaining to cover the other product liability claims pending against the Company. Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiovascular and vascular surgeries throughout the United States and Canada. The Company's BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels and is CE marked in the European Community and approved in Canada for use in soft tissue repair and approved in Australia for use in vascular and pulmonary sealing and repair. The Company also manufactures the SynerGraft(R) Vascular Graft, which is CE marked for distribution within the European Community. Statements made in this press release that look forward in time or that express management's beliefs, expectations or hopes are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These future events may not occur as and when expected, if at all, and, together with the Company business, are subject to various risks and uncertainties. Such risks and uncertainties include that current and future product liability litigation may not be resolved within the limits of the Company's insurance policies or may otherwise be resolved in a manner that is materially adverse to the Company, that current securities and derivative based claims may not be resolved within the limits of the Company's insurance policies or may otherwise be resolved in a manner that is materially adverse to the Company, and other risk factors detailed in CryoLife's Securities and Exchange Commission filings, including CryoLife's Form 10-K filing for the year ended December 31, 2002, and the Company's other SEC filings. For additional information about the company, visit CryoLife's web site: http://www.cryolife.com END 1604691 -----END PRIVACY-ENHANCED MESSAGE-----